MedTrace Logo

Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients

NCT00420355 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2009-02-06

No results posted yet for this study

Summary

The objective of this study is to determine the pharmacokinetics of lopinavir, ritonavir, and atazanavir when lopinavir/ritonavir and atazanavir are used in combination.

Conditions

  • HIV Infection

Interventions

DRUG

atazanavir

Atazanavir 300 mg daily on Days 6-12.

DRUG

lopinavir/ritonavir

Lopinavir/ritonavir 400 mg/100 mg twice daily on Days 6-16, then 800 mg/200 mg daily on Days 17-21.

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • R. Chris Rathbun, Pharm.D. · University of Oklahoma

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2007-10-31
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00420355 on ClinicalTrials.gov